Stockreport
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
- Tablet authorization builds upon established use of LIVMARLI oral solution in Canada TORONTO--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized the tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).LIVMARLI had previously been authorized in Canada as an oral solution for the treatment of cholestatic pruritus in patients with ALGS aged 12 months or older. The tablet formulation complements the existing 9.5 mg/ml oral solution, offering an additional dosing option for patients with ALGS weighing 22 kg or more who are able to swallow tablets.“LIVMARLI’s tablet formulation provides an important new option for patients with ALGS,” said Jamie Twiselton, General Manager, Mirum Pharmaceuticals Canada. “With a liquid formulation for younger patients and a convenient one tablet per dose option available for older patien
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MIRM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MIRM alerts
MIRM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
NEWS
NEWS
- Mirum Pharmaceuticals (NASDAQ:MIRM) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating.[MarketBeat]
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 [Yahoo! Finance][Yahoo! Finance]
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026[Business Wire]
- Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $130.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)[Business Wire]
- More
MIRM
SEC Filings
SEC Filings
- 2/17/26 - Form 4
- 2/17/26 - Form SCHEDULE
- 2/13/26 - Form 144
- MIRM's page on the SEC website
- More